Purpose: To investigate the role of combined systemic and local chemotherapy in improving the survival of patients with vitreoretinal lymphoma (VRL). Methods: Patients with VRL consecutively seen from 2006 to 2020 were retrospectively reviewed; data on the presence and time of central nervous system (CNS) involvement and treatment regimen (systemic, local or combined chemotherapy) were collected. Overall survival (OS) and progression-free survival (PFS) were calculated for each group. Results: Forty-three eyes of 22 subjects with histology-proven VRL were included. Mean time of survival was 64.8 months (SE +/- 10.8). Twelve patients (57%) presented CNS involvement, which was significantly associated with progression (r = 0.48, P = .03) and death (r = 0.56, P = .009). The isolated primary VRL group had a 5-year OS of 80%. Combined systemic and local chemotherapy reduced the risk of death by 82% (hazard ratio 0.18[0.04- 0.85]) in the entire cohort. Conclusion: Combined systemic and local chemotherapy significantly improved OS but not PFS of patients affected by VRL.
Survival and recurrence in vitreoretinal lymphoma simulating uveitis at presentation: the possible role of combined chemotherapy / Gozzi, F; Aldigeri, R; Mastrofilippo, V; De Simone, L; Bolletta, E; Marzano, J; Iannetta, D; Coassin, M; Ilariucci, F; Ferrari, A; Luminari, S; Merli, F; Croci, S; Zerbini, A; Farnetti, E; Nicoli, D; Valli, R; Tamagnini, I; Cavazza, A; Salvarani, C; Fontana, L; Cimino, L. - In: OCULAR IMMUNOLOGY AND INFLAMMATION. - ISSN 0927-3948. - 30:7-8(2022), pp. 1-9. [10.1080/09273948.2021.1962916]
Survival and recurrence in vitreoretinal lymphoma simulating uveitis at presentation: the possible role of combined chemotherapy
Iannetta D;
2022
Abstract
Purpose: To investigate the role of combined systemic and local chemotherapy in improving the survival of patients with vitreoretinal lymphoma (VRL). Methods: Patients with VRL consecutively seen from 2006 to 2020 were retrospectively reviewed; data on the presence and time of central nervous system (CNS) involvement and treatment regimen (systemic, local or combined chemotherapy) were collected. Overall survival (OS) and progression-free survival (PFS) were calculated for each group. Results: Forty-three eyes of 22 subjects with histology-proven VRL were included. Mean time of survival was 64.8 months (SE +/- 10.8). Twelve patients (57%) presented CNS involvement, which was significantly associated with progression (r = 0.48, P = .03) and death (r = 0.56, P = .009). The isolated primary VRL group had a 5-year OS of 80%. Combined systemic and local chemotherapy reduced the risk of death by 82% (hazard ratio 0.18[0.04- 0.85]) in the entire cohort. Conclusion: Combined systemic and local chemotherapy significantly improved OS but not PFS of patients affected by VRL.| File | Dimensione | Formato | |
|---|---|---|---|
|
Gozzi_Survival and_2022.pdf
accesso aperto
Note: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
1.04 MB
Formato
Adobe PDF
|
1.04 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
